Neurimmune Receives Major Development Milestone upon Initation of Global Phase 3 Studies with Aducanumab for Early Alzheimer’s Disease
Leading program for
Alzheimer's disease in
Phase 3 clinical trials.
program for Parkinson in Phase 1.
RTM™ Technology Platform:
Creating an entirely novel
generation of drugs with
excellent safety and efficacy
profiles by reverse
Neurimmune is a biopharmaceutical company dedicated to the development of innovative immunotherapeutics for human diseases. Its Reverse Translational Medicine™ platform generates recombinant human monoclonal antibodies with unique therapeutic properties. Together with target selectivity and high affinities these antibodies combine superior risk profiles with excellent efficacy.
Neurimmune has partnered four antibody programs with Biogen Idec. Antibody Aducanumab (BIIB037) for Alzheimer's disease is currently in Phase 3 clinical trials. The therapeutic antibody for Parkinson’s disease (BIIB054) is in Phase 1. Therapeutic antibodies for tauopathies and fronto-temporal dementia are in preclinical stages.
Neurimmune’s program packages for amyotrophic lateral sclerosis, transthyretin amyloidosis and type-2 diabetes are validated with preclinical proof-of-concept. They are ready for partnering